ArticleInternational journal of clinical and experimental medicine2014
Prognostic value and efficacy valuation of postoperative intravesical instillation in primary urothelial carcinomas of upper urinary tract.
Article in International journal of clinical and experimental medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.
- Single-dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma.The Cochrane database of systematic reviews · 2019Pooled it
- [Nephroureterectomy for upper tract urothelial carcinoma : Effectiveness of single-dose intravesical chemotherapy].Der Urologe. Ausg. A · 2020Review
- Optimal Management of Upper Tract Urothelial Carcinoma: an Unmet Need.Current treatment options in oncology · 2019Review
- Evaluation of Intraoperative Versus Postoperative Adjuvant Mitomycin C with Nephroureterectomy for Urothelial Carcinoma of the Upper Urinary Tract.Bladder cancer (Amsterdam, Netherlands) · 2018Article
- Perioperative treatments for resected upper tract urothelial carcinoma: a network meta-analysis.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder tumor recurrence after surgery for upper urinary tract urothelial carcinoma (UUT-UC) is frequent. Intravesical instillation has been widely accepted as an effective way to prevent bladder tumor recurrence. We aimed to find whether postoperative instillation have benefits for bladder tumor recurrence of UUT-UC. A meta-analysis based on 6 studies from 5 publications was performed. Published literature from PubMed, EMBASE and Web of science was pooled and the hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to estimate the benefits. Conclusively, our results indicate a 62% benefit (HR = 0.38; 95% CI: 0.16-0.87) in recurrence free survival (RFS) among those treated with postoperative intravesical instillation compared with those not. Mitomycin C (MMC) and pirarubicin were found to provide more benefits than other regimens in stratified analysis. Further, after excluding one study for its heterogeneity, the results demonstrated a more reliable results of a 34% benefit (HR = 0.66; 95% CI = 0.44-0.98). This study reveals a relative benefit for postoperative instillation to improve the RFS of UUT-UC patients.
Indexed as
Identifiers
25663970PMC4307417W2296435131What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.